Evidence map›Paper›PMID 38559000›Full record

ArticlebioRxiv : the preprint server for biology2024

Variant mutation in SARS-CoV-2 nucleocapsid enhances viral infection via altered genomic encapsidation.

Hannah C Kubinski, Hannah W Despres, Bryan A Johnson, Madaline M Schmidt, Sara A Jaffrani, Margaret G Mills, Kumari Lokugamage, Caroline M Dumas, David J Shirley, Leah K Estes and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Hannah C KubinskiDepartment of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington VT, 05405, USA.
Hannah W DespresDepartment of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington VT, 05405, USA.ORCID 0000-0003-0321-5202
Bryan A JohnsonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Madaline M SchmidtDepartment of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington VT, 05405, USA.ORCID 0000-0003-3893-3466
Sara A JaffraniDepartment of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington VT, 05405, USA.
Margaret G MillsVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle WA 98195, USA.ORCID 0000-0002-0493-9408
Kumari LokugamageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Caroline M DumasDepartment of Biology, University of Vermont 109 Carrigan Drive, 120A Marsh Life Sciences, Burlington VT 05404, USA.
David J ShirleyFaraday, Inc. Data Science Department. Burlington VT, 05405, USA.
Leah K EstesDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Andrew PekoszW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0003-3248-1761
Jessica W CrothersDepartment of Pathology and Laboratory Medicine, Robert Larner, MD College of Medicine, University of Vermont, Burlington, VT, USA.
Pavitra RoychoudhuryVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle WA 98195, USA.ORCID 0000-0002-4567-8232
Alexander L GreningerVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle WA 98195, USA.ORCID 0000-0002-7443-0527
Keith R JeromeVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle WA 98195, USA.
Bruno Martorelli Di GenovaDepartment of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington VT, 05405, USA.ORCID 0000-0001-9983-1856
David H WalkerDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Bryan A BallifDepartment of Biology, University of Vermont 109 Carrigan Drive, 120A Marsh Life Sciences, Burlington VT 05404, USA.
Mark S LadinskyDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA. 91125, USA.ORCID 0000-0002-1036-3513
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA. 91125, USA.
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0001-8803-7606
Emily A BruceDepartment of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington VT, 05405, USA.ORCID 0000-0001-8391-370X
University of Vermont · USThe University of Texas Medical Branch at Galveston · USUniversity of Washington · USCalifornia Institute of Technology · USFaraday Technology (United States) · USJohns Hopkins University · US

Funding

Using Dengue Controlled Human Infection Model to Identify Adaptive Immune Correlates of ProtectionP20GM125498 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Ellen Kozelka · 2018 to 2026
$24.9M
The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responsesP01AI165075 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2022 to 2023
$10.7M
Vermont Immunology/Infectious Diseases CenterP30GM118228 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BUDD, RALPH C · 2016 to 2021
$6.8M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
Understanding the Development of Mucosal Immunity to Poliovirus: Adjuvants and Modulation of the Enteric MicrobiotaK23AI175660 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Jessica W. Crothers · 2024 to 2026
$485k
NIAID NIH HHS K23 AI175660NIAID NIH HHS P01 AI165075NIAID NIH HHS R01 AI153602NIGMS NIH HHS P20 GM125498NIGMS NIH HHS P30 GM118228
6 · The paper itself

Abstract

The evolution of SARS-CoV-2 variants and their respective phenotypes represents an important set of tools to understand basic coronavirus biology as well as the public health implications of individual mutations in variants of concern. While mutations outside of Spike are not well studied, the entire viral genome is undergoing evolutionary selection, particularly the central disordered linker region of the nucleocapsid (N) protein. Here, we identify a mutation (G215C), characteristic of the Delta variant, that introduces a novel cysteine into this linker domain, which results in the formation of a disulfide bond and a stable N-N dimer. Using reverse genetics, we determined that this cysteine residue is necessary and sufficient for stable dimer formation in a WA1 SARS-CoV-2 background, where it results in significantly increased viral growth both

Identifiers

PMID38559000
PMCPMC10979914
OpenAlexW4392713964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.